Clinical pharmacology of camptothecins

Cancer Chemotherapy and Pharmacology, Supplement

Volumn 42, Issue , 1998, Pages

  Iyer, Lalitha ^a   Ratain, Mark J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

9 Aminocamptothecin; Camptothecins; Clinical pharmacology; Irinotecan; Topotecan

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; IRINOTECAN; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; CONFERENCE PAPER; DIARRHEA; DNA SYNTHESIS; DRUG METABOLISM; DRUG SOLUBILITY; DRUG TOXICITY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NEUTROPENIA; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 0031714683     PISSN: 09439404     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051077     Document Type: Conference Paper

References (137)

1. Abigerges D, Chabot GG, Armand JP, Herait P, Gouyette A, Gandia D (1995) Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13:210
2. Aktipis S (1986) DNA: the replicative process and repair. In: Devlin TM (ed) Textbook of biochemistry with clinical correlations. John Wiley and Sons, New York, Chichester, Brisbane, Toronto, Singapore, p 625
3. Aräki E, Ishikawa M, Lido M, Koide T, Itabashi M, Hoshi A (1993) Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 84:697
4. Armand JP (1996) CPT-11: clinical experience in phase I studies. Sem Oncol 23:27
5. Barilero I, Gandia D, Armand JP, Mathieu-Boue A, Re M, Gouyette A, Chabot GG (1992) Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients. J Chromatogr 575:275
6. Barnett AA (1996) FDA approve bark-derived drug. Lancet 347:1613
7. Betcher DL, Burnham N (1992) Topotecan. J Ped Oncol Nurs 9:31
8. Beijnen JH, Smith BR, Keijer WJ, van Gijn R, ten Bokkel Huinink WW, Vlasveld LT, Rodenhuis S, Underberg WJ (1990) High-performance liquid chromatographic analysis of the new antitumor drug SK&F 104864-A (NSC 609699) in plasma. J Pharm Biomed Anal 8:789
9. Bissery MC, Vrignaud P, Lavelle F (1996) Preclinical antitumor activity and pharmacokinetics of irinotecan (CPT-11) in tumor-bearing mice. Ann NY Acad Sci 83:173
10. Blaney SM, Balis FM, Cole DE, Craig C, Reid JM, Ames MM, Krailo M, Reaman G, Hammond D, Poplack DG (1993a) Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res 53:1032
11. Blaney SM, Cole DE, Balis FM, Godwin K, Poplack DG (1993b) Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res 53:725
12. Blaney SM, Cole DE, Godwin K, Sung C, Poplack DG, Balis FM (1995) Intrathecal administration of topotecan in nonhuman primates. Cancer Chemother Pharmacol 36:121
13. Bosma PJ, Roy Chowdhury J, Huang, T-J, Lahiri P, Bakker C, Gantla S, Oude Elferink PJO, Van Es HHG, Lederstein M, Whitington P, Jansen PLM, Roy Chowdhury N (1992) Mechanisms of inherited deficiencies of multiple UDP-glucuronosyltransferase isoforms in two patients with Crigler-Najjar syndrome, type I. FASEB J 6:2859
14. Bosma PJ, Seppen J, Goldhoorn B, Oude Elferink RPJ, Roy Chowdhury J, Roy Chowdhury N, Jansen PLM (1994) Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem 269:17960
15. Bosma PJ, Roy Chowdhury J, Bakker C, Gantla S, Boer A, Oostra BA, Lindhout D, Tytgat GNJ, Jansen PLM, Elferink RPJO, Chowdhury NR (1995) The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 333:1171
16. Bowman LC, Stewart CF, Zamboni WC, Crom WR, Luo X, Heideman R, Houghton R, Houghton PJ, Meyer WH, Pratt CB (1996) Toxicity and pharmacodynamics of oral topotecan in pediatric patients with solid tumors. Proc Am Soc Clin Oncol 15:462
17. Broom C (1996) Clinical studies of topotecan. Ann NY Acad Sci 803:264
18. Burris HA, Hanauske AR, Marshall MH, Kuhn JG, Hilsenbeck SG, von Hoff DD (1992) Activity of topotecan, a new topoisomerase I inhibitor, against human colony-forming units in vitro. J Natl Cancer Inst 84:1816
19. Burris HA III, Awada A, Kuhn JG, Eckardt JR, Cobb PW, Rinaldi DA, Fields S, Smith L, Von Hoff DD (1994) Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion. Anticancer Drugs 5:394
20. Burris HA III, Gerrits CJH, Schellens JHM (1996) Oral topotecan for 10 days daily and twice daily every 3 weeks: a phase I and pharmacologic study in adults. Ann Oncol 79 (suppl 5):126
21. Chabot GG (1995) Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38. Cancer Chemother Pharmacol 36:463
22. Chabot GG (1996) Clinical pharmacology and pharmacodynamics of irinotecan. A review. Ann NY Acad Sci 83:164
23. Chabot GG, Abigerges D, Catimel G, Culine S, de Forni M, Extra JM, Mahjoubi M, Herait P, Armand JP, Bugat R (1995) Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 6:141
24. Clinical Brochure 9-Amino-20(S)-camptothecin, NSC 603071 (1992) Investigational New Drug Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland, USA
25. Cole DE, Blaney SM, Balis FM (1995) Topotecan in physiologic fluids: depot of active drug in red blood cells. Proc Am Assoc Cancer Res 36:363
26. Creemers GJ, Lund B, Verweij J (1994) Topoisomerase I inhibitors: Topotecan and irinotecan. Cancer Treat Rev 20:73
27. Creemers GJ, Gerrits CJH, Eckardt JR, Schellens JHM, Burris HA, Planting AST, Rodriguez GI, Loos WJ, Hudson I, Broom C, Verweij J, Von Hoff DD (1997) Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J Clin Oncol 15:1087
28. Crigler JF, Najjar VA (1952) Congenital familial nonhemolytic jaundice with kernicterus. Pediatrics 10:169
29. Dahut W, Harold N, Takimoto C, Allegra C, Chen A, Hamilton JM, Arbuck S, Sorensen M, Grollman F, Nakashima H, Lieberman R, Liang M, Corse W, Grem J (1996) Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients J Clin Oncol 14:1236
30. Dancey J, Eisenhauer EA (1996) Current perspectives on camptothecins in cancer treatment. Br J Cancer 74:327
31. de Forni M, Bugat R, Chabot GG, Culine S, Extra JM, Gouyette A, Madelaine I, Marty ME, Mathieu-Boue A (1994) Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 54:4347
32. Drengler R, Burris H, Dietz A, Eckardt J, Eckardt G, Hodges S, Kraynak M, Kuhn J, Peacock N, Rinaldi D, Rizzo J, Rodriguez G, Schaaf L, Smith L, Thurman A, Von Hoff D (1996). A phase I trial to evaluate orally administered irinotecan HCl (CPT-11) given daily × 5 every 3 weeks in patients with refractory malignancies. Proc Am Assoc Clin Oncol 15:489
33. Eder JP, Rubin E, Stone R, Bryant M, Xu G, Supko J, Kinchla N, Lynch T, Hurwitz S, Rodriguez D, Shapiro C, Toppmeyer D, Grossbard M, Vosburg E, Huberman M, Schnipper L, Shulman L, Kufe DW (1996) Trials of 9-amino-20(S)-camptothecin in Boston. Ann NY Acad Sci 83:247
34. Emerson DL, Besterman JM, Roger Brown H, Evans MG, Leitner PP, Luzzio MJ, Shaffer JE, Sternbach DD, Uehling D, Vuong A (1995) In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues. Cancer Res 55:603
35. Fagbemi S, Iyer L, Mani S, Vogelzang NJ, Cohn H, Fasanmade A, Ratain MJ (1997a) Phase I and pharmacokinetic study of irinotecan (CPT-11) administered with cyclosporine A (CSA). Proc Am Soc Clin Oncol 16:219a
36. Friedman HS, Houghton PJ, Schold SC, Keir S, Bigner DD (1994) Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 34:171
37. Gilbert A, Lereboullet P (1901) La cholémie simple familiale. La Semaine Medicale 21:241
38. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R, Potmesil M (1989) DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246:1046
39. Gottlieb JA, Guarino AM, Call JB, Oliverio VT, Block JB (1970) Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54:461
40. Grochow LB, Rowinsky EK, Johnson R, Ludeman S, Kaufmann SH, McCabe FL, Smith BR, Hurowitz L, DeLisa A, Donehower RC, Noe DA (1992) Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Met Dispos 20:706
41. Gupta E, Lestingi TM, Mick R, Ramírez J, Vokes EE, Ratain MJ (1994) Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 54:3723
42. Gupta E, Safa AR, Wang X, Ramirez J, Ratain MJ (1996) Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A. Cancer Res 56:1309
43. Gupta E, Ratain MJ (1997a) Camptothecin analogues: topotecan and irinotecan. In: Grochow LB, Ames M (eds) A clinician's guide to chemotherapy: pharmacokinetics and pharmacodynamics. Williams & Wilkins, Baltimore (in press)
44. Gupta E, Rosemarie M, Ramirez J, Wang X, Lestingi TM, Vokes EE, Ratain MJ (1997b) Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 15:1502
45. Gupta E, Wang X, Ramírez J, Ratain MJ (1997c) Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol 39:440
46. Haas NB, La Creta FP, Walczak J, Hudes GR, Brennan JM, Ozols RF, O'Dwyer PJ (1994) Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Cancer Res 54:1220
47. Haaz MC, Rivory LP, Riché C, Robert J (1997) Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A (CYP3A) and drug interactions. Proc Am Assoc Cancer Res 38:17
48. Hare CB, Elion GB, Houghton PJ, Houghton JA, Keir S, Marcelli SL, Bigner DD, Friedman HS (1997) Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 39:187
49. Herben VM, ten Bokkel Huinink WW, Beijnen JH (1996) Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 31:85
50. Hertzberg RP, Caranfa MJ, Hecht SM (1989a) On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzymeDNA complex. Biochemistry 28:4629
51. Hertzberg RP, Caranfa MJ, Holden KG, Jakas DR, Gallagher G, Mattern MR, Mong SM, Bartus JO, Johnson RK, Kingsbury WD (1989b) Modification of the lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 32:715
52. Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci RZ, Blum RH (1994) Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen. J Clin Oncol 12:553
53. Houghton PJ, Cheshire PJ, Myers L, Houghton JA (1992) Evaluation of 9-dimethylaminomethyl-10-hydroxy camptothecin (topotecan) against xenografts derived from adult and childhood tumors. Ann Oncol 3 (suppl 1):84
54. Hsiang YH, Hertzberg R, Hecht S, Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873
55. Hsiang YH, Lihou MG, Liu LF (1989) Arrest of replication forks by drug stabilized topoisomerase IDNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49:5077
56. Iyer L, Roy SK, Ratain MJ (1996) In vitro glucuronidation of SN-38, the active metabolite of irinotecan (CPT-11) in human liver microsomes. Proc Am Soc Clin Oncol 15:1589
57. Iyer L, King CD, Tephly T, Ratain MJ (1997a) UGT isoform 1.1 (UGT*1.1) glucuronidates SN-38, the active metabolite of irinotecan. Proc Am Soc Clin Oncol 16:201a
58. Iyer L, Whitington PF, Roy SK, Ratain MJ (1997b) Genetic basis for the glucuronidation of SN-38: role of UGT*1 isoform. Clin Pharmacol Ther 61:164
59. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, Ratain MJ (1997c) Genetic predisposition to the metabolism of irinotecan (CPT-11): role of UGT isoform 1A1 (UGT1A1) in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest (in press)
60. Jones SF, Burris HA (1996) Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Pract 4:51
61. Kaneda N, Nagata H, Furuta T, Yokokura T (1990a) Metabolism and pharmacokinetics of camptothecin analogue CPT-11 in the mouse. Cancer Res 50:1715
62. Kaneda N, Yokokura T (1990b) Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res 50:1721
63. Kantarjian HM, Beran M, Ellis A, Zwelling L, O'Brien S, Cazenave L, Koller C, Rios MB, Plunkett W, Keating MJ, Estey EH (1993) Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood 81:1146
64. Kawato Y, Aonuma M, Matsumoto K, Sato K (1991a) Production of SN-38, a main metabolite of the camptothecin derivative CPT-11, and its species and tissue specificities. Yakubutsu Dotai 6:899
65. Kawato Y, Nagata T, Furuta T, Yokokura T (1991b) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the anti-tumor effect of CPT-11. Cancer Res 51:4187
66. Kawato Y, Sekiguchi M, Akahane K, Tsutomi Y, Hirota Y, Kuga H, Suzuki W, Hakusui H, Sato K (1993) Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats. J Pharm Pharmacol 45:444
67. Kuhn J, Rizzo J, Eckardt J (1995) Phase I bioavailability study of oral topotecan. Proc Am Soc Clin Oncol 14:1538
68. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M (1987) Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47:5944
69. Li LH, Fraser TJ, Bhuyan OBK (1972) Action of camptothecin on mammalian cells in culture. Cancer Res 32:2643
70. Liang MD, Dahut W, Quin MF, Harold N, Arbuck SG, Chen A, Hamilton JM, Sorensen JM, Allegra CJ, Grem JL, Takimoto CH (1996) Preclinical and clinical studies of a new colloidal dispersion formulation of 9-Aminocamptothecin. Proc Am Assoc Cancer Res 37:432
71. Liehr JG, Ahmed AE, Giovanella B (1996) Pharmacokinetics of camptothecins administered orally. Ann NY Acad Sci 83:157
72. Liu LF, Duann P, Li C, D'arpa P, Wu J (1996). Mechanism of action of camptothecin. Ann NY Acad Sci 83:44
73. Mani S, Iyer L, Janisch L, Wang X, Fleming GF, Schilsky RL, Ratain MJ (1997) Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). Proc Am Soc Clin Oncol 16:201a
74. McCabe FL, Johnson RK (1994) Comparative activity of oral and parenteral topotecan in murine tumor models: Efficacy of oral topotecan. Cancer Invest 12:308
75. McLeod HL, Douglas F, Oates M, Symonds RP, Prakash D, van-der-Zee AG, Kaye SB, Brown R, Keith WN (1994) Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int J Cancer 59:607
76. Mick R, Gupta E, Vokes EE, Ratain MJ (1996) Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity. J Clin Oncol 14:2012
77. Minami H, Mick R, Yokes EE, Ratain MJ (1996) Pharmacodynamic models for leukopenia and thrombocytopenia of 9-amino-camptothecin (9-AC). Proc Am Soc Clin Oncol 15:179
78. Moertel CG, Schutt AJ, Reitemeier RJ, RG Hahn (1972) Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56:95
79. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B (1996) Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 347:578
80. Moore A, Imondi A, L'Heureux D (1997) Preclinical evaluation of three dosage schedules of 9-aminocamptothecin (9AC) for the treatment of spontaneous lymphoma in dogs. Proc Am Assoc Cancer Res 38:75
81. Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS (1972) Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 56:515
82. Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Niitani H, Taguchi T (1991) Phase I study of weekly intravenous infusions of CPT-11, and new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 83:1164
83. Ohe Y, Sasaki Y, Shinkai T, Eguchi K, Tamura T, Kojima A, Kunikane H, Okamoto H, Karato A, Ohmatsu H, Kanzawa F, Saijo N (1992) Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 84:972
84. O'Reilly S, Rowinsky E, Slichenmyer W, Donehower RC, Forastiere A, Ettinger D, Chen TL, Sartorius S, Grochow LB (1996a) Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 14:3062
85. O'Reilly S, Rowinsky E, Slichenmyer W, Donehower RC, Forastiere A, Ettinger D, Chen TL, Sartorius S, Bowling K, Smith J, Brubaker A, Lubejko B, Ignacio V, Grochow LB (1996b) Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. J Natl Cancer Inst 88:817
86. Pantazis P, Hinz HR, Mendoza JT, Kozielski AJ, Williams LJ Jr, Stehlin JS Jr, Giovanella BC (1992) Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res 52:3980
87. Pastori A, Farao M, Geroni C, Porro MG, Grandi M (1997) Antitumor activity of 9-aminocamptothecin (9-AC) by s.c. and oral route. Proc Am Assoc Cancer Res 38:18
88. Potmesil M, Giovanella BC, Wall ME, Liu LF, Silber R, Stehlin JS, Wani MC, Hochster H (1993) Preclinical and clinical development of DNA topoisomerase I inhibitors in the United States. In: Andoh T, Ikeda H, Oguro M (eds) Molecular biology of topoi somerases and its application to chemotherapy. CRC, Nagoya, p 301
89. Potmesil M, Arbuck SG, Takimoto CH, Liebes L, Hochster H (1996) 9-aminocamptothecin and beyond, preclinical and clinical studies. Ann NY Acad Sci 83:231
90. Pratt CB, Stewart C, Santana VM, Bowman L, Furman W, Ochs J, Marina N, Kuttesch JF, Heideman R, Sandlund JT, Avery L, Meyer WH (1994) Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol 12:539
91. Pratesi G, Tortoreto M, Corti C, Giardini R, Zunino F (1995) Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts. Br J Cancer 71:525
92. Ratain MJ, Mick R, Gupta E, Lestingi TM, Schilsky RL, Vokes EE (1996) Prospective evaluation of the effect of race and gender on irinotecan (CPT-11) pharmacokinetics (PK) and intestinal toxicity. Proc Am Soc Clin Oncol 15:472
93. Recondo G, Abbruzzese J, Newman B (1991) A phase I trial of topotecan administered by a 24-h infusion. Proc Am Assoc Cancer Res 32:206
94. Rivory LP, Robert J (1994) Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. J Chromatogr 661:133
95. Rivory LP, Robert J (1995) Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative, irinotecan. Cancer Chemother Pharmacol 36:176
96. Rivory LP, Riou JF, Haaz MC, Sable S, Vuilhourgne M, Commercon A, Pond SM, Robert J (1996) Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res 56:3689
97. Rothenberg ML (1996a) CPT-11: an original spectrum of clinical activity. Semin Oncol 23:21
98. Rothenberg ML (1996b) The current status of irinotecan (CPT-11) in the United States. Ann NYAcad Sci 83:272
99. Rothenberg ML, Kuhn JG, Burris HA III, Nelson J, Eckardt JR, Tristan-Morales M, Hilsenbeck SG, Weiss GR, Smith LS, Rodrigues GI, Rock MK, Von Hoff DD (1993) Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11:2194
100. Rougier P, Bugat R (1996) CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Semin Oncol 23:34
101. Rowinsky EK, Gorchow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH, Donehower RC (1992) Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 10:647
102. Rowinsky EK, Grochow LB, Ettinger DS (1994) Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 54:427
103. Rubin E, Wood V, Bharti A, Trites D, Lynch C, Hurwitz S, Bartel S, Levy S, Rosowsky A, Toppmeyer D, Kufe D (1995) A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin Cancer Res 1:269
104. Saltz L, Sirott M, Young C, Tong DN, Tzy-Jyun Y, Tao Y, Tochanowski B, Wright P, Barbosa K, Toomasi F, Kelsen D (1993) Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 85:1499
105. Sasaki Y, Hakusui H, Mizuno S, Morita M, Miya T, Eguchi K, Shinkai T, Tamura T, Ohe Y, Saijo N (1995a) A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Jpn J Cancer Res 86:101
106. Sasaki Y, Yoshida Y, Sudoh K, Hasusui H, Fujii H, Ohtsu T, Wakita H, Igarashi T, Itoh K (1995b) Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11. Cancer Res 86:111
107. Sasaki Y, Mizuno S, Fujii H, Ohtsu T, Wakita H, Igarashi T, Itoh K, Sekine I, Miyata Y, Saijo N (1995c) A limited sampling model for estimating pharmacokinetics of CPT-11 and its active metabolite SN-38. Jpn J Cancer Res 86:117
108. Schaaf L, Ichhpurani N, Elfring G, Wolf D, Rothenberg M, Von Hoff D (1997) Influence of age on the pharmacokinetics of irinotecan (CPT-11) & its metabolites, SN-38 and SN-38 glucuronide (SN-38G), in patients with previously treated colorectal cancer. Proc Am Soc Clin Oncol 16:202a
109. Schellens JHM, Eckardt JR, Creemers GJ, Loos WJ, McDonald M, Broom C, Davies BE, Verweij J, van Hoff DD (1995) Pharmacokinetics, clinical pharmacodynamics and safety of chronic oral topotecan in a phase I study. Proc Am Soc Clin Oncol 14:457
110. Schellens JHM, Creemers GJ, Beijnen JH, Rosing H, de Boer-Dennert M, McDonald M, Davies B, Verwij J (1996) Bioavailability and pharmacokinetics of oral topotecan: A new topoisomerase I inhibitor. Br J Cancer 73:1268
111. Shimada Y, Rothenberg M, Hilsenbeck SG, Burris HA, Degen D, Von Hoff DD (1994) Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. Anticancer Drugs 5: 202
112. Slichenmyer WJ, Rowinsky EK, Grochow LB, Kaufmann SH, Donehower RC (1994) Camptothecin analogues: studies from the Johns Hopkins Oncology Center. Cancer Chemother Pharmacol 34:553
113. Slichenmyer WJ, Donehower RC (1995) Recent clinical advances with camptothecin analogues. Cancer Treat Res 78:29
114. Sparreboom A, Stoter G, Loos WJ, Nooter K, Punt CJA, Calajori E, Verweij J (1997) Oral bioavailability of 9-aminocamptothecin in adult patients with solid tumors. Proc Am Assoc Cancer Res 38:75
115. Stewart CF, Baker SD, Heideman RL, Jones D, Crom WR, Pratt CB (1994) Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J Clin Oncol 12:1946
116. Stewart CF, Zamboni WC, Crom WR, Houghton PJ (1997) Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice. Cancer Chemother Pharmacol 40:259
117. Supko JG, Malspeis L (1992). Liquid chromatographic analysis of 9-aminocamptothecin in plasma monitored by fluorescence induced upon postcolumn acidification. J Liq Chromatogr 15:3261
118. Takasuna K, Hagiwara T, Hirohshi M, Kato M, Nomura M, Nagai E, Yokoi T, Kamataki T (1996) Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56:3752
119. Takimoto CH, Klecker RW, Dahut WL, Yee LK, Strong JM, Allegra CJ, Grem JL (1994) Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extration and high-performance liquid chromatography. J Chromatogr 655:97
120. Takimoto CH, Dahut W, Harold N, Nakashima H, Lieberman R, Liang MD, Arbuck SG, Chen AP, Hamilton JM, Cantilena LR, Allegra CJ, Grem JL (1996) Clinical pharmacology of 9-amino-camptothecin. Ann NY Acad Sci 83:324
121. Takimoto CH, Dahut W, Marino MT, Nakashima H, Liang MD, Harold N, Leiberman R, Arbuck S, Band RA, Chen AP, Hamilton JM, Cantilena LR, Allegra CJ, Grem JL (1997) Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-amino-camptothecin in adult cancer patients. J Clin Oncol 15:1492
122. Tsuji T, Kaneda N, Kado K, Yokokura T, Yoshimoto T, Tsuru D (1991) CPT-11 converting enzyme from rat serum: purification and some properties. J Pharmacobiodyn 14:341
123. Tubergen DG, Stewart CF, Pratt CB, Zamboni WC, Winick N, Santana VM, Dryer ZA, Kurtzberg J, Bell B, Grier H, Vietti TJ (1996) Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 18:352
124. van Warmerdam LJC, Venveij J, Rosing, Schellens JHM, Maes RAA, Beijnen JH (1994) Limited sampling models for topotecan pharmacokinetics. Ann Oncol 5:259
125. van Warmerdam LJC, Bokkel Huinink WW, Rodenhuis S, Koier I, Davies BE, Rosing H, Maes RAA, Beijnen JH (1995a) Phase 1 clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion. J Clin Oncol 13: 1768
126. van Warmerdam LJC, Venveij J, Schellens JHM, Rosing H, Davies BE, de Boer-Dennert M, Maes RAA, Beijinen JH (1995b) Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother Pharamacol 35:237
127. van Warmerdam LJC, Creemers GJ, Rodenhuis S, Rosing H, de Boer-Dennert M, Schellens JHM, Huinink WWB, Davies BE, Maes RAA, Venveij J, Beijnen JH (1996) Pharmacokinetics and pharmacodynamics of topotecan given on a daily-time-five schedule in phase II clinical trials using a limited-sampling procedure. Cancer Chemother Pharmacol 38:254
128. Vassal G, Terrier-Lacombe MJ, Bissery MC, Venuat AM, Gyergyay F, Benard J, Morizet J, Boland I, Ardouin P, Bressac-de-Paillerets B, Gouyette A (1996) Therapeutic acitivity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neruoblastoma. Br J Cancer 74:537
129. Verweij J, Lund B, Bijnen J, Planting A, de Boer-Dennert M, Koier I, Rosing H, Hansen H (1993) Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 4:673
130. Von Hoff DD, Burris HA III, Eckardt J, Rothenberg M, Fields SM, Chen SF, Kuhn JG (1994) Preclinical and phase I trials of topoisomerase I inhibitors. Cancer Chemother Pharmacol 34:S41
131. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim GA (1966) Plant antitumor agents: I. The isolation and structure of camptothecin, a novel alkaloidal leukemia tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88:3888
132. Wall JG, Burris HA III, Von Hoff DD, Rodriguez G, Kneuper-Hall R, Shaffer D, O'Rourke T, Brown T, Weiss G, Clark G, McVea S, Brown J, Johnson R, Friedman C, Smith B, Mann WS, Kuhn J (1992) A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anticancer Drugs 3:337
133. Wasserman E, Myara A, Paumier D, Herait P, Awad L, Misset JL, Cvitkovic E (1997) Baseline bilirubin (bil) and its transient early increase predicts likelihood of severe neutropenia and diarrhea in CPT-11-based chemotherapy. Proc Am Soc Clin Oncol 16:219a
134. Wani MC, Ronman PE, Lindley JT, Wall ME (1980) Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues. J Med Chem 23:554
135. Wani MC, Nicholas AW, Wall ME (1986) Plant antitumor agents. 23. Synthesis and biological activity of camptothecin analogues. J Med Chem 29:2358
136. Willson JKV (1996) Topoisomerase-I inhibitors in the management of colon cancer. Ann NY Acad Sci 803:256
137. Yamamoto N, Tamura T, Nishiwaki Y, Kawakami Y, Abe S, Nakabayashi T, Suzuki S, Matsuda T, Hayashi I, Takahashi T, Saijo N (1997) Limited sampling model for the area under the concentration versus time curve of irinotecan and its application to a multicentric phase II trial. Clin Cancer Res 3:1087